The short answer: same day is fine, different injection sites are required, same syringe is not allowed
Our dual-peptide approach combines the collagen-boosting power of GHK-Cu with the cellular rejuvenation benefits of NAD+, creating a comprehensive anti-aging strategy that addresses multiple pathways of skin aging simultaneously
+ 70 % Collagen Synthesis vs 50% vitamin C and 40% retinoic acid in comparative in vitro models 4 000+ Genoa Gene Expression 31.2% of the human genome modulated: 1,942 genes activated, 762 deleted, 47 DNA repair genes 30 - 50 % Hair follicles Increased hair follicle size documented in hair studies 401.91 Da Molecular Weight GHK + Cu complex CAS 89030-95-5 | Formula CHNOCu -55.8 % Wrinkle Volume 12-week, double-blind, placebo-controlled facial study (71 women) Mechanism of Action Multi-Path Regeneration Epigenetic modulation, collagen synthesis and copper transport Primary Pathway Gene Expression Epigenetic Modulation GHK-Cu modulates the expression of over 4,000 human genes (31.2% of the genome)
Note: Nearly all data is from animal or in vitro models
Cagrilintide as a standalone drug does not appear to be pursuing separate FDA approval at this time, as Novo Nordisk is focusing on the combination product
We always infuse slowly